'Fund it properly or it will implode': parting comments from Aginus Kalis on EU drug regulatory network
This article was originally published in SRA
“If you don’t finance it correctly, it will implode.” This was the stark warning key European drug regulator Aginus Kalis gave about the European drug regulatory network in an exclusive interview to Scrip Regulatory Affairs on his last day as executive director of the Dutch Medicines Evaluation Board.
You may also be interested in...
A continuous two-way dialogue on Brexit between the European Medicines Agency and industry is a must. The EMA is tentatively planning three Brexit-related events for stakeholders and, in the meantime, it wants companies to keep it abreast of their plans for products affected by the UK’s departure from the EU
The sponsors of up to seven new drugs or vaccines will find out this week whether their products will soon be approved in the EU. The products include two vaccines from Sanofi and what is possibly the first generic rival to Bayer's Xarelto to be assessed by the European Medicines Agency.
Takeda will soon seek EU approval of its dengue vaccine candidate. The marketing application will be fast-tracked, as will the applications for Regeneron's evinacumab and bluebird bio's eli-cel Lenti-D gene therapy.